Stock Ratings / Health Care / NBIX / financials

HALO (75) EXEL (89) TWST (52) TECH (72) ⌘ Pro Terminal →

Neurocrine Biosciences Inc. (NBIX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$146.38 +0.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Neurocrine Biosciences Inc. (NBIX) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (96% profit margin, 16% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $14.88B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NBIX)Realized 20D OHLCV Swing Band: ±4.8%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NBIX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$748.7M (26.2% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.89B

FY24

Rev $2.36B

FY25

Rev $2.86B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$2.86B	98.2%	21.6%	$478.6M	$748.7M	15.5%
FY 2024	$2.36B	98.6%	24.2%	$341.3M	$557.2M	15.7%
FY 2023	$1.89B	92%	13.3%	$249.7M	$305.0M	4%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NBIX)

✓Walkthrough of NBIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NBIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.18%▲ RESISTANCE BREAKOUT

2026-11-01O $145.5H $146.4L $145.5C $146.4VOL 831.6K

RES: $137.5SUP: $126.7SMA50: $146.5SMA200: $147.4

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NBIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NBIX Butterfly Map → + Track NBIX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

24.0%/yr Implied 5Y Growth

vs. +21.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NBIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NBIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NBIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NBIX)

Health Care Rank #44 of 188 ⚔️ HALO vs NBIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NBIX vs. HALO, EXEL, TWST, TECH)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (26 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, Neurocrine Biosciences Inc. (NBIX) ranks #44 by composite RQD confidence (73/100, grade B) and #81 by equity capitalization ($14.88B). Within this direct 5-issuer industry benchmark cohort, EXEL leads on earnings valuation at 21.0x trailing P/E, while EXEL leads on capital efficiency and profitability with 35.1% ROIC and 96.0% gross margin. EXEL currently holds the highest overall quantitative score in the immediate peer group at 89/100 (A) compared with NBIX at 73/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NBIX ACTIVE Neurocrine Biosciences Inc.	B	73/100	31.1x	96.0%	15.7%	+0.58%	$14.88B	Benchmark Subject
HALO Halozyme Therapeutics Inc.	B	75/100	47.0x	83.6%	18.0%	+0.88%	$14.89B	/halo-vs-nbix →
EXEL Exelixis Inc.	A	89/100	21.0x	96.0%	35.1%	-0.12%	$16.40B	/exel-vs-nbix →
TWST Twist Bioscience Corporation	D+	52/100	—	94.2%	-11.7%	0.00%	$11.50B	/twst-vs-nbix →
TECH Bio-Techne Corp	B	72/100	155.3x	64.8%	3.4%	+0.03%	$11.40B	/tech-vs-nbix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000914475

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neurocrine Biosciences Inc. (NBIX) reported GAAP revenue of $2.86B (+21.4% vs. FY2024 revenue of $2.36B , and +51.6% cumulative change since FY2023) , GAAP net income of $478.6M, operating cash flow of $782.7M, and free cash flow of $748.7M (+34.4% YoY). On the balance sheet, NBIX closed FY2025 with $4.63B in total assets against $620.3M in total debt (Altman Z-Score: 8.13, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.86B	$478.6M	$782.7M	$748.7M	$4.63B	$620.3M
FY2024 (FY)	2024-12-31	$2.36B	$341.3M	$595.4M	$557.2M	$3.72B	$508.1M
FY2023 (FY)	2023-12-31	$1.89B	$249.7M	$389.9M	$305.0M	$8.18B	$1.91B

3. NBIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NBIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Neurocrine Biosciences Inc. (NASDAQ: NBIX) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $146.38 (+0.58% 1D, market cap $14.88B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 15/20. Across 188 tracked Health Care issuers, NBIX ranks #44 in composite RQD confidence.

How does NBIX compare to HALO and EXEL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), NBIX carries a Roarable B (73/100 RQD), trailing P/E of 31.1x, gross margin of 96.0%, and ROIC of 15.7%. By comparison, HALO (Halozyme Therapeutics Inc.) holds a B grade (75/100 RQD, P/E 47.0x, ROIC 18.0%, cap $14.89B) and EXEL (Exelixis Inc.) posts a A grade (89/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.40B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NBIX?

Per NBIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000914475), Neurocrine Biosciences Inc. generated $2.86B in revenue (+21.4% YoY), $478.6M in net income, and $748.7M in free cash flow against $4.63B in total assets and $620.3M in total debt. Key quantitative strengths: Strong cash generator (96% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NBIX trading relative to its 50-day, 200-day, and 52-week technical levels?

NBIX last traded at $146.38 (+0.58% on volume of 831,620 shares), positioning the stock -0.09% below its 50-day simple moving average ($146.51) and -0.72% below its 200-day simple moving average ($147.44). Across its 52-week range of $122.14 to $186.12, NBIX sits at the 37.9% percentile with a 14-day RSI of 56.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.8% ($139.35 to $153.41).

NBIX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Neurocrine Biosciences Inc. (NBIX)?

In FY 2025 (10-K), NBIX converted $2.9B of revenue into a 98.2% gross margin, 21.6% operating margin, and $748.7M in free cash flow (26.2% FCF margin).

Direct Sub-Reports: NBIX RQD Cockpit NBIX 12M Forecast NBIX Earnings & Move NBIX Dividends & DRIP NBIX Insiders & 13F NBIX Whale Options NBIX Profit Sankey NBIX News & Why